Dare Bioscience (DARE) Competitors $2.11 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.11 0.00 (-0.19%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DARE vs. SKYE, IFRX, HLVX, SRZN, ONCY, IOBT, EQ, ANEB, VTGN, and TCRXShould you be buying Dare Bioscience stock or one of its competitors? The main competitors of Dare Bioscience include Skye Bioscience (SKYE), InflaRx (IFRX), HilleVax (HLVX), Surrozen (SRZN), Oncolytics Biotech (ONCY), IO Biotech (IOBT), Equillium (EQ), Anebulo Pharmaceuticals (ANEB), VistaGen Therapeutics (VTGN), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry. Dare Bioscience vs. Its Competitors Skye Bioscience InflaRx HilleVax Surrozen Oncolytics Biotech IO Biotech Equillium Anebulo Pharmaceuticals VistaGen Therapeutics TScan Therapeutics Skye Bioscience (NASDAQ:SKYE) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability. Is SKYE or DARE more profitable? Dare Bioscience's return on equity of 0.00% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -76.03% -69.20% Dare Bioscience N/A N/A -103.70% Which has preferable earnings and valuation, SKYE or DARE? Dare Bioscience has higher revenue and earnings than Skye Bioscience. Skye Bioscience is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$1.06-4.01Dare Bioscience$10K2,844.28-$4.05M-$2.14-0.99 Do institutionals and insiders believe in SKYE or DARE? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 4.5% of Skye Bioscience shares are held by company insiders. Comparatively, 4.8% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend SKYE or DARE? Skye Bioscience currently has a consensus price target of $15.50, suggesting a potential upside of 264.71%. Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 373.93%. Given Dare Bioscience's higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Dare Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SKYE or DARE? In the previous week, Skye Bioscience had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 5 mentions for Skye Bioscience and 4 mentions for Dare Bioscience. Skye Bioscience's average media sentiment score of 0.95 beat Dare Bioscience's score of 0.73 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SKYE or DARE? Skye Bioscience has a beta of 2.34, indicating that its stock price is 134% more volatile than the S&P 500. Comparatively, Dare Bioscience has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. SummarySkye Bioscience beats Dare Bioscience on 9 of the 15 factors compared between the two stocks. Get Dare Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for DARE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DARE vs. The Competition Export to ExcelMetricDare BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$28.44M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-0.9921.1774.5225.93Price / Sales2,844.28463.28536.78122.58Price / CashN/A46.6837.5660.44Price / Book-3.069.6112.166.29Net Income-$4.05M-$53.29M$3.28B$270.77M7 Day Performance-1.86%0.29%0.98%3.36%1 Month Performance3.94%8.91%7.20%6.41%1 Year Performance-37.01%13.14%63.06%28.26% Dare Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DAREDare Bioscience2.2946 of 5 stars$2.11flat$10.00+373.9%-35.3%$28.44M$10K-0.9930Short Interest ↓SKYESkye Bioscience2.1046 of 5 stars$3.50+0.6%$15.50+342.9%-32.9%$108.46MN/A-3.3011IFRXInflaRx3.2425 of 5 stars$1.60+36.8%$6.60+312.5%+2.1%$107.41M$180K-2.0060News CoveragePositive NewsShort Interest ↓Gap UpHigh Trading VolumeHLVXHilleVax1.5849 of 5 stars$2.09+0.5%$2.00-4.3%+22.2%$104.79MN/A-1.4620Short Interest ↑SRZNSurrozen2.967 of 5 stars$12.19+4.4%$38.50+215.8%+36.0%$104.43M$10.65M-0.8580Positive NewsGap DownHigh Trading VolumeONCYOncolytics Biotech2.3996 of 5 stars$1.04-2.8%$5.00+380.8%+38.6%$104.38MN/A-3.8530Gap UpIOBTIO Biotech3.2836 of 5 stars$1.58flat$8.67+448.5%+134.4%$104.09MN/A-1.0030Positive NewsEQEquillium0.7713 of 5 stars$1.74-4.4%$1.00-42.5%+134.1%$103.54M$41.10M-3.1140Short Interest ↓ANEBAnebulo Pharmaceuticals2.4593 of 5 stars$2.50-0.8%$5.50+120.0%+13.6%$102.71MN/A-9.624News CoveragePositive NewsGap UpVTGNVistaGen Therapeutics0.9992 of 5 stars$3.34+3.4%N/A+11.1%$102.47M$490K-1.8840Short Interest ↑TCRXTScan Therapeutics3.4062 of 5 stars$1.80-1.1%$7.80+333.3%-67.5%$102.15M$2.82M-1.65100Positive News Related Companies and Tools Related Companies Skye Bioscience Alternatives InflaRx Alternatives HilleVax Alternatives Surrozen Alternatives Oncolytics Biotech Alternatives IO Biotech Alternatives Equillium Alternatives Anebulo Pharmaceuticals Alternatives VistaGen Therapeutics Alternatives TScan Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DARE) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dare Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dare Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
